Jazz Pharmaceuticals Research UK Limited, the manufacturer of EPIDIOLEX® (cannabidiol) oral solution, is conducting the EPIDIOLEX Pregnancy Surveillance Program. This is an observational study to evaluate the pregnancy-related health outcomes in women who have taken at least 1 dose of EPIDIOLEX in the 13 days before their last menstrual period prior to pregnancy or anytime during pregnancy and their babies up to 12 months of age who were exposed to at least 1 dose of EPIDIOLEX in utero. In addition, participants will be asked to provide health information about their pregnancy and their infant's growth and development up to their first birthday.
Participation in this study will not impact maternal or infant standard of treatment or care as decided by healthcare providers.
If you would like to learn more about the Pregnancy Surveillance Program or are interested in enrolling in the study:
Call Toll-Free
Hours of operation:
Monday - Friday
9:00 a.m. to 5:00 p.m. Eastern Time
Report a PregnancyNotify your healthcare provider right away if you or your loved one become pregnant or plan to become pregnant while on EPIDIOLEX.
If you or your loved one are able and willing to provide consent for the Pregnancy Surveillance Program verbally, you may be eligible to participate if:
You or your loved one has taken at least 1 dose of EPIDIOLEX in the 13 days before the last menstrual period prior to pregnancy or any time during pregnancy.
You can enroll even if you or your loved one are no longer pregnant.